Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling

2021 ◽  
Vol 100 ◽  
pp. 108129
Author(s):  
Xiaohe Li ◽  
Buri Xi ◽  
Yang Miao ◽  
Xiaoyang Ma ◽  
Jianwei Zhang ◽  
...  
Keyword(s):  
2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jia-jia Qian ◽  
Qi Xu ◽  
Wei-min Xu ◽  
Ren Cai ◽  
Gui-cheng Huang

Abstract Background Anterior cruciate ligament transection surgery (ACLT)-induced OA model was often used to investigate the molecular mechanism of knee osteoarthritis (KOA). Researches have shown that vascular endothelial growth factor (VEGF) played an important role in OA. The present study aimed to investigate the pathological changes after ACLT surgery and reveal the expression characteristics of the VEGF-A/VEGFR2 signaling pathway in this model. Methods Moderate KOA model was established by ACLT, and 1, 2, 4, 8, and 12 weeks after surgery, hematoxylin-eosin (HE) and Safranin-O(S-O) staining were used to detect the pathological changes in mouse knee cartilage, and the matrix biomarkers A Disintegrin and Metalloproteinase with Thrombospondin Motifs 5(ADAMTS5), Collagen II (COL-II) were detected using immunohistochemistry (IHC), CD31 was detected by immunofluorescence (IF) to show the vascular invasion in cartilage, and proteins expression of VEGF-A pathway were detected by Western blot (WB). Meanwhile, the inflammatory biomarkers cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in cartilage were detected by WB. Results ACLT surgery can lead to degeneration of cartilage in mice, and the characteristics of the lesion were time-dependent. The ADAMTS5-positive cells increased while COL-II decreased in OA cartilage with time, and new blood vessels labeled by CD31 can be seen from 1 week in OA cartilage, and increased in 8 and 12 weeks. The expression of VEGF-A, VEGFR2, COX-2, and iNOS were higher than control groups, which were basically consistent with the degree of osteoarthritis. Conclusions The degenerative degree of articular cartilage was time-dependent; angiogenesis and inflammation were important pathological changes of cartilage in KOA. The expression of the VEGF-A/VEGFR2 signaling pathway was basically correlated with the degree of KOA.


2016 ◽  
Vol 10 (4) ◽  
pp. 347-354 ◽  
Author(s):  
Chandran S. Abhinand ◽  
Rajesh Raju ◽  
Sasikumar J. Soumya ◽  
Prabha S. Arya ◽  
Perumana R. Sudhakaran

2016 ◽  
Vol 12 (7) ◽  
pp. 1853-1861 ◽  
Author(s):  
Ashish A. Kulkarni ◽  
Vijay Elakkya Vijaykumar ◽  
Siva Kumar Natarajan ◽  
Shiladitya Sengupta ◽  
Venkata S. Sabbisetti

2017 ◽  
Vol 403 ◽  
pp. 305-317 ◽  
Author(s):  
Zhenyu Zhong ◽  
Mengge Huang ◽  
Mengxin Lv ◽  
Yunfeng He ◽  
Changzhu Duan ◽  
...  

Marine Drugs ◽  
2015 ◽  
Vol 13 (2) ◽  
pp. 861-878 ◽  
Author(s):  
Shih-Wei Lin ◽  
Shih-Chung Huang ◽  
Hsiao-Mei Kuo ◽  
Chiu-Hua Chen ◽  
Yi-Ling Ma ◽  
...  

2021 ◽  
Author(s):  
Chul Min Kim ◽  
Yun-Mi Jeong ◽  
Jae-Hun Kim ◽  
Guolong Jin ◽  
Hyeongkwon Oh ◽  
...  

Abstract Thymosin β-4 is a 43-amino acid intracellular polypeptide that was originally isolated from bovine thymus. Of the 16 known thymosin families, thymosin β-4 is the most common type found in all tissues. Thymosin β-4 regulates angiogenesis, cell differentiation, morphogenesis, migration, and organogenesis and is linked to a dynamic equilibrium between G-actin and F-actin. In particular, thymosin β-4 is well-known for its angiogenic and anti-apoptotic functions. In this study, we synthesized thymosin β-4 linked with the well-known cell-penetrating peptide TAT (YGRKKRRRQRRR). TAT-thymosin β-4 promotes angiogenesis and cell migration in vitro via the VEGFR2 signaling pathway and reduces apoptosis. To examine angiogenic potential in vivo, a Matrigel Plus assay was conducted that revealed the angiogenic effect of TAT-thymosin β-4. In conclusion, TAT-thymosin β-4 promotes blood vessels and is expected to be applicable in regenerative medicine for all organs requiring blood vessels.


Biomedicines ◽  
2020 ◽  
Vol 8 (8) ◽  
pp. 252
Author(s):  
Jang Mi Han ◽  
Ye Seul Choi ◽  
Dipesh Dhakal ◽  
Jae Kyung Sohng ◽  
Hye Jin Jung

Targeting angiogenesis is an attractive strategy for the treatment of angiogenesis-related diseases, including cancer. We previously identified 23-demethyl 8,13-deoxynargenicin (compound 9) as a novel nargenicin A1 analog with potential anticancer activity. In this study, we investigated the antiangiogenic activity and mode of action of compound 9. This compound was found to effectively inhibit in vitro angiogenic characteristics, including the proliferation, invasion, capillary tube formation, and adhesion of human umbilical vein endothelial cells (HUVECs) stimulated by vascular endothelial growth factor (VEGF). Furthermore, compound 9 suppressed the neovascularization of the chorioallantoic membrane of growing chick embryos in vivo. Notably, the antiangiogenic properties of compound 9 were related to the downregulation of VEGF/VEGFR2-mediated downstream signaling pathways, as well as matrix metalloproteinase (MMP)-2 and MMP-9 expression in HUVECs. In addition, compound 9 was found to decrease the in vitro AGS gastric cancer cell-induced angiogenesis of HUVECs by blocking hypoxia-inducible factor-1α (HIF-1α) and VEGF expression in AGS cells. Collectively, our findings demonstrate for the first time that compound 9 is a promising antiangiogenic agent targeting both VEGF/VEGFR2 signaling in ECs and HIF-1α/VEGF pathway in tumor cells.


Sign in / Sign up

Export Citation Format

Share Document